However, new autoimmune drugs Skyrizi and Rinvoq resulted in a 3.9% increase ... with a number of upcoming treatments (still ...

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...

AbbVie shares, which hit a 52-week high in late October after the drugmaker posted quarterly earnings that topped Wall Street's expectations and raised its dividend by nearly 6%, were recently down ...

Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative ...

Hepion is a biopharmaceutical company headquartered in Edison, New Jersey, previously focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

Engineered polymers interfere with protein interactions to protect cell health in a mouse study. Researchers at Northwestern University and Case Western Reserve University have developed the first ...